Global Molecular Diagnostics Market is Expected to Reach Nearly $36.5 Billion by 2018

May 29, 2013

In 2012, the global DNA diagnostics market was valued at more than $17.3 billion. The total market is projected to grow at a compound annual growth rate (CAGR) of 12.6% from 2013 through 2018 to reach nearly $36.5 billion by 2018.

Within the global DNA diagnostics market, the market for polymerase chain reaction-based diagnostic assays claimed the largest share in 2012 with an estimated $8.3 billion. The PCR diagnostics market is projected to grow at a five-year CAGR of 11.5% to reach $16.3 billion by 2018.

The fastest-growing segment of the DNA diagnostics market is the biochip/lab-on-a-chip (LOAC) market, which was valued at $1.7 billion in 2012. It is projected to increase at a CAGR of 17% to reach $4.6 billion by 2018. The market for microarray diagnostic assays was valued at $3.9 billion in 2012 and is projected to grow at a CAGR of 12.4% to reach $8.2 billion by 2018. The market for in situ hybridization diagnostic assays was valued at nearly $3.3 billion in 2012 and is projected to increase at a CAGR of 12.8% to reach nearly $7.1 billion by 2018.

Molecular diagnostics and molecular imaging for diagnostics have benefited greatly from research conducted since the completion of the Human Genome Project.

 RSS Feeds – Biotechnology

Biomarkers are playing increasingly important roles, and one disease area, cancer, is getting much attention in this regard. Technologies such as DNA microarrays are being used to analyze biological samples in molecular diagnostics to identify high-risk patients, predict response to therapy, and monitor patients during treatment to either determine effectiveness of treatment or detect recurrence of disease. Numerous companies are developing molecular oncology diagnostics tests.

Molecular screens for oncology applications will be one of the key drivers for the clinical use of diagnostics. Total demand for products in this area is projected to grow at a CAGR of 13.4% from 2013 to 2018. While microarrays are and will remain the top revenue contributors during the forecast period, the highest growth will be seen in the development and approval of novel biochips. Microarray revenues equaled $1.8 billion in 2012 and will grow by a CAGR of 13.2% to reach $4 billion in 2018. Biochips are projected to increase at a CAGR of 19.9% and reach $2.5 billion in 2018.

Molecular Diagnostics: Technologies and Global Markets (BIO063B) examines the global market for assays used to detect specific nucleic acid sequences in medical and life-sciences applications. While the goal of all DNA-based diagnostic assays is similar, several different technologies can be employed. BCC analyzes each technology in detail, determines major players and current market status, and presents forecasts of growth over the next five years. Scientific challenges and advances, including the latest trends, are emphasized. We examine government regulations, major collaborations, recent patents, and factors affecting the industry worldwide. In addition, we examine new directions for DNA diagnostic technologies and emerging applications in clinical



Global DNA Diagnostics Market is Expected to Reach Nearly $36.5 Billion in 2018

March 22, 2013

Focusing on the requirements of the research market has enabled molecular diagnostic manufacturers to devote resources to product development and technological improvements.  Future growth opportunities will depend largely on clinical applications for molecular diagnostics, a market with a different set of requirements for success than the large-scale academic and commercial research market.  For manufacturers to realize the full potential of the core technological strengths of their products in the clinical market, they will need to partner or develop ancillary strengths in medical affairs, regulatory affairs, reimbursement and marketing to a broad base of physicians, hospital administrators and third-party payers.
The commercial interest and growth in Rx/Dx companion diagnostics is being driven largely by advancements in oncology research. One molecular diagnostic research source stated that few if any oncology drugs will receive FDA approval in the future without a companion diagnostic to ensure that the therapeutic is administered to genetically compatible patients. Infectious disease treatments will also benefit from companion molecular diagnostics although not to the same extent as cancer therapies.
Partnerships and alliances will occur along the complete product pipeline spectrum—springing from early concept testing, concurrent research or product development, financial collaborations and commercial expertise synergies as in marketing or manufacturing collaborations.

Clinical diagnostics customers are more differentiated than academic and research customers. While sophisticated researchers can readily translate molecular diagnostic product features directly into benefits, clinical customers will require more detailed educational sales efforts. Vendors will need to develop marketing programs to educate different customer constituencies using cost/benefit information and the specific terminology that each finds compelling. Physicians will want to know how products will improve their ability to diagnose and rapidly and accurately provide personalized patient treatment, while insurers and hospital administrators will be interested in understanding how products will reduce costs and improve the financial efficiency of care. Success in the clinical market will require significant investment in sales and marketing staff and program development and/or partnering with firms that have this organization in place.

 RSS Feeds – Biotechnology

Molecular Diagnostics: Technologies and Global Markets (BIO063B) provides:

  • An overview of the global market for molecular diagnostics
  • Analyses of global market trends, with data from 2010 through 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • Discussion of related issues, such as government regulation, reimbursement through insurance, patient confidentiality, and other legal ramifications

To provide further information about this report we offer a Complimentary Introduction, available from our Website. To download, simply click here, go to the Table of Contents tab, add the complimentary introduction to your cart, and confirm your order.


Stem Cell Development Continuing at a Blistering Speed

August 1, 2008


Wellesley, Mass—According to a new technical market research report, STEM CELL TECHNOLOGY: CURRENT APPLICATIONS AND FUTURE DIRECTIONS (BIO035C) from BCC Research, the domestic market for stem cell technology is expected to increase from $112.0 million in 2007 to $423.1 million in 2012, a compound annual growth rate (CAGR) of 30.5%

The market is divided into cellular therapeutics and therapeutic banking categories. Stem cells in therapeutic banking have the larger share of the market, worth $65.9 million in 2007 and expected to increase to $155.7 million in 2012, for a CAGR of 18.8%.

Cellular therapeutics should be the faster growing segment. Cellular therapeutics generated $46.1 million in 2007 and is expected to generate $267.4 million in 2012, a CAGR of 42.1%.

The advent of stem cell technology has reignited the regenerative medicine market with hopes of powerful new therapeutics geared towards addressing unmet healthcare needs such as cardiovascular disease, neurological diseases, metabolic diseases, organ failure, a wide range of injuries, and even age related degeneration.

Although stem cell based therapeutics hold great promise, the delivery of actual readily available treatments is still projected to be at least five if not 10 or more years away. People looking to capitalize on the potential future therapeutic applications of stem cells have been preserving their stem cells, and stem cell banking has become a slow but growing market.

Stem cell research and development will continue to play a significant role in the present and future commercialization of stem cell based products and services and may develop into a substantial parallel market to stem cell based therapeutics as these tools mature, and potentially move into adjacent life science markets such as pharmaceutical testing and drug discovery.

Contact: Jason W. Prokowiew

Tel: 978-870-3345


read more | digg story

Bookmark and Share

Global Market for DNA Diagnostics Technologies

July 8, 2008

According to a new technical market research report, DNA DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS (BIO063A) from BCC Research, the global market for DNA diagnostics technology is expected to be worth $10.6 billion in 2008.

read more | digg story

Bookmark and Share